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GASTROINTESTINAL DISORDERS—
Clinical Outcomes Studies
PGI1
COMORBIDITIES DURING THE YEAR FOLLOWING
DIAGNOSIS FOR PERSONS WITH AND WITHOUT GERD
USING THE AGENCY FOR HEALTH RESEARCH AND QUALITY
(AHRQ) 261 SPECIFIC CATEGORIES
Wallander MA1,Wahlqvist P1, Kleinman N2, Campbell S2,Talley NJ3,
Brook R4
1AstraZeneca R&D, Mölndal, Sweden, 2The HCMS Group, Cheyenne,
WY, USA, 3Mayo Clinic, Jacksonville, FL, Rochester, MN, USA, 4The
JeSTARx Group, Newfoundland, NJ, USA
OBJECTIVES: Evaluate the prevalence and costs of selected
comorbidities in GERD patients using a systematic approach.
METHODS: An employer database query of >300,000 US
employees from 2001–2005 to identify subjects with GERD
ICD9s and a cohort without GERD (Control). For each GERD
subject 10 control patients were matched using logistic regres-
sion and propensity scores from demographic differences, region,
and the Charlson Comorbidity Index Score. Analysis focused on
the 12 months post-diagnosis (Dx). Direct medical cost data
were inﬂated to constant dollars and assigned based on ICD9
codes from the AHRQ’s 261 Speciﬁc Categories. Prevalence rates
were based on persons within the cohort with claims for each
category. Average costs for each category were calculated for the
entire cohort. Prevalence comparisons used z-scores of log odds
ratios (Woolf method), and the average cost comparisons used
Sattherthwaite t-tests. RESULTS: Data were available for 11,653
GERD and 116,530 matched controls. Differences between cases
with GERD and controls are presented as: (% prevalence in
GERD: % prevalence in controls, $ cost in GERD: $ cost in con-
trols). Gastrointestinal disorders: Abdominal pain (27.3%
GERD : 6.8% Control, $165 GERD : $32 Control); Gastritis +
duodenitis (15.2% : 1.0%, $87 : $5); GI hemorrhage (6.6% :
1.8%, $37 : $9); Stomach/duodenum disorders (5.4% : 0.5%,
$17 : $1); Noninfectious gastroenteritis (5.0% : 1.6% $19 : $5);
Biliary tract disease (3.9% : 0.7%, $150 : $25); Gastroduodenal
ulcer (2.5% : 0.2%, $11 : $1); Other GI disorders (30.8% : 3.6%,
$116 : $13); Respiratory disorders: Upper respiratory infections
(31.5% : 18.0%, $64 : $23); Asthma (6.9% : 2.8%, $23 : $7);
COPD+bronchiectasis (4.9% : 2.4%, $10 : $6); Other upper res-
piratory disease (21.0% : 8.5%, $79 : $24); Other lower respira-
tory disease (17.6% : 6.8%, $52 : $19); Other disorders:
Nonspeciﬁc chest pain (18.8% : 6.2%, $163 : $46); Nutrit/
endocrine/metabolic (8.6% : 3.3%, $159 : $23); Thyroid disor-
ders (8.0% : 4.8%, $31 : $12). All costs and prevalence of comor-
bidities were higher in the GERD cohort compared to controls
(P < 0.05). CONCLUSION: Patients with GERD have more
prevalent conditions than subjects without GERD. From an
insurer’s perspective, this increased burden for GERD sufferers
is also associated with higher costs.
PGI2
BIOLOGICAL AGENTS FOR THE MANAGEMENT OF CROHN’S
DISEASE IN ADULTS:A SYSTEMATIC REVIEW, META-ANALYSIS
AND MULTIPLE TREATMENT COMPARISON
Hughes D1, Kikuchi T1, Bodger K2
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OBJECTIVES: To conduct a systematic review of the clinical
effectiveness of biological agents in adult Crohn’s disease (CD),
a meta-analysis of treatment effect, and an indirect comparison
of individual therapies. METHODS: Searches were conducted to
identify RCTs assessing efﬁcacy of monoclonal antibodies to
TNF (inﬂiximab, certolizumab pegol and adalimumab), inter-
feron (fontolizumab) and a selective adhesion molecule inhibi-
tor (natalizumab) in adult CD. A meta-analysis, applying the
Mantel-Haenszel test, was used to estimate the pooled odds ratio
for all agents (versus placebo), assuming a ﬁxed effects model.
Indirect comparisons among treatments, for remission (CDAI <
150) at the end of the induction and maintenance phases, were
made by use of a Bayesian analysis of indirect evidence for mul-
tiple treatments. RESULTS: Fifteen studies were identiﬁed; 1 for
fontolizumab; 2 each for certolizumab and adalimumab; 3 for
natalizumab and 7 for inﬂiximab. These were categorised
broadly into: (1) single and (2) multiple dose induction studies
with placebo control group; maintenance studies without
placebo control group after (3) single and (4) multiple dose
induction; and (5) maintenance studies with placebo control
group after multiple dose induction. Biological agents were supe-
rior to placebo at the end of induction (pooled OR = 1.61,
95%CI 1.22–2.13; heterogeneity I2 = 0%, 95%CI 0%-64%).
End of maintenance studies were deemed too heterogeneous 
(I2 = 89%, 95%CI 62%-95%) for analysis. The multiple treat-
ment comparison analysis suggested that at the end of induction,
the probability that inﬂiximab is best is 77% (SD 42%);
fontolizumab 21% (41%); certolizumab and natalizumab 1%.
For maintenance, the probability that adalimumab is best is 60%
(SD 49%); inﬂiximab 33% (47%); natalizumab 7% (25%); cer-
tolizumab <1%. CONCLUSION: Several agents have shown
superiority to placebo in moderate-to-severe CD. Head-to-head
trial data for rival agents are lacking but a multiple treatment
comparison analysis (acknowledging the limitations) failed to
identify an individual agent as dominant for both induction and
maintenance end-points.
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CONSTIPATION IN PERSONS RECEIVING HOSPICE CARE:
PRELIMINARY ESTIMATES
Strassels SA1, Reifsnyder J2, Maxwell T2
1University of Texas at Austin College of Pharmacy, Austin,TX, USA,
2excelleRx, Inc, Philadelphia, PA, USA
OBJECTIVES: Pain at the end of life is common and often sub-
optimally treated, though treatment of pain can also result in
adverse events. One of these adverse events is constipation,
which can interfere with pain management, health-related
quality of life, and result in avoidable medical resource use. The
epidemiology of constipation in persons at the end of life remains
incompletely described, thus we sought to determine the preva-
lence and severity of constipation among persons receiving
hospice care in the United States from 2000 to 2004.
METHODS: Data for this study were obtained from excelleRx,
Inc., a national provider of pharmaceutical services to US hos-
pices. Patient-level information included primary diagnosis (by
ICD-9 code), type of hospice care received, constipation inten-
sity, and prescription of opioid analgesics. Constipation intensity
during the previous 24 hours was assessed by hospice nurses
using a 0–10 numeric rating scale (NRS; 0 = none, 10 = worst)
at admission and periodically during hospice care. RESULTS:
During the study period, 347,555 discharged or deceased
persons received hospice services; 55% of these persons were
female, 87% were Caucasian, and mean age was 75 years. Con-
stipation was assessed at least once for 180,239 (45%) individ-
uals, an average of 3 times per person. Overall, mean intensity
of constipation was mild, though moderate and severe constipa-
tion was reported by 29,132 (8%) and 13,748 (4%) of persons,
respectively. Among individuals who reported severe constipa-
tion at least once, 67% had a primary diagnosis of cancer. CON-
CLUSION: Moderate to severe constipation was reported at
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least once by a substantial percentage of persons in this study.
These data provide insight into care for persons at the end of
life, particularly among persons with cancer. Furthermore, this
information may be useful as a process indicator of the quality
of end of life care.
GASTROINTESTINAL DISORDERS—Cost Studies
PGI4
INCLUSION OF A PENTAVALENT ROTAVIRUS VACCINE IN
THE NEW ZEALAND CHILDHOOD IMMUNISATION
SCHEDULE
Milne RJ1, Grimwood K2, Saunders K3
1University of Auckland, Auckland, New Zealand, 2University of
Otago, Wellington, New Zealand, 3Health Outcomes Associates Ltd,
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OBJECTIVES: To estimate: (i) the current rotavirus burden in
New Zealand children less than 5 years of age; and (ii) the annual
health beneﬁts, budget impact and cost- effectiveness of includ-
ing Rotateq, a pentavalent live-attenuated oral rotavirus vaccine,
in the annual Childhood Immunisation Schedule. METHODS:
A spreadsheet model was based on local epidemiology and costs
plus the ﬁndings of a large phase III clinical trial showing that
RotaTeq had 94.5% efﬁcacy against rotavirus hospital presen-
tations and 86.0% against non-urgent medical visits. In the base
case, vaccine uptake was 85% and the annual discount rate was
5%. RESULTS: We predict annually 1356 admissions, 2781 ED
presentations and 9495 primary-care consultations at an annual
societal cost of $7.8M ($27.68/child; two-thirds Government,
one-third caregivers). Vaccinating successive birth cohorts
becomes increasingly effective and cost-effective as more children
become immune. After ﬁve years (assuming 85% annual uptake
of 3 doses), 7936 cases seeking medical attention (1105 admis-
sions, 2215 ED presentations, 6941 primary-care consultations)
would be averted. At an acquisition cost of $50/dose, the incre-
mental cost to Government is $6.41 M in year-1 and $3.35 M in
year-5. Societal cost in year-5 would be $1301 to avert one hos-
pitalisation and $139 to avert one health care presentation. The
annual cost to Government is $3.38 M to avert 7936 cases of
paediatric rotavirus gastroenteritis that would otherwise require
medical attention. The incremental cost and cost/admission
averted are moderately sensitive to rotavirus incidence rates,
declining protection over 5 years (if any), and vaccine unit price,
but robust to uncertainty in other parameters. The budget impact
of vaccination will lessen slightly and the cost-effectiveness will
improve slightly beyond year-5, provided protective efﬁcacy is
maintained in school-aged children. CONCLUSION: Addition
of a pentavalent rotavirus vaccine to the New Zealand Child-
hood Immunisation Schedule would confer important clinical
gains at a modest annual cost.
PGI5
PHARMACOECONOMICS OF CHRONIC HEPATITIS C 
IN SLOVAKIA
Bielik J
Trencin University,Trencˇín, Slovak Republic
OBJECTIVES: To investigate the cost-effectiveness of therapy of
chronic hepatitis C with peginterferon alfa-2b and ribavirin in
the context of the Slovak health care system. METHODS: We
retrospectively obtained clinical data on the cost of treatment in
140 patients with chronic hepatitis C or advanced chronic liver
disease of other etiology. Life-time cost of untreated and treated
chronic hepatitis C was calculated using the Markov model and
cost-effectiveness of antiviral therapy was evaluated by cost per
life-year saved (LYS) analysis. RESULTS: The average medical
cost per patient-year in case of chronic hepatitis C not treated
with antiviral drugs, compensated cirrhosis, complicated cirrho-
sis, and after liver transplantation was 578 USD Sk (33,50 Slovak
crowns = 1 USD), 926 USD, 5890 USD, and 9997 USD, respec-
tively. The cost per life-year saved using 3% discounting was
3156 USD in the average group of patients and 5711 USD in
patients with genotype 1. In patients with genotype 2 and 3
antiviral treatment would result in a life-time cost saving of 492
USD per patient. CONCLUSION: The cost of treatment of
chronic hepatitis C and other chronic liver diseases in Slovakia
is comparable with countries with more advanced economies.
The treatment of chronic hepatitis C with peginterferon alfa-2b
and ribavirin in Slovakia is cost-effective based on pharma-
coeconomic calculations.
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BURDEN OF POST-OPERATIVE ILEUS (POI) IN COLECTOMY
SURGERY PATIENTS IN THE UNITED STATES
Iyer S1, Saunders W2
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OBJECTIVES: To study the impact of post-operative ileus (POI)
on health care utilization and costs in colectomy surgery patients
in the United States. METHODS: A retrospective cohort study
design was used. Adult patients with a principal procedure code
for colectomy (ICD-9 codes 45.71–45.79), discharged between
Jan. 2004 and Dec. 2004 were identiﬁed from Premier’s Per-
spective Comparative Database, an inpatient records database
from over 500 hospitals in the United States. The colectomy
patients were further classiﬁed for the presence of POI, deﬁned
as presence of paralytic ileus (ICD-9 code 560.1) and/or diges-
tive system complications (ICD-9 code 994.1) during the study
period. Hospital length of stay (LOS), ICU LOS, ventilator
usage, and hospitalization costs were compared using t-tests and
chi-square tests as appropriate. RESULTS: A total of 17,896
patients with primary procedure code for colectomy were iden-
tiﬁed, of which 3115 (17.4%) patients were classiﬁed for pres-
ence of POI, including paralytic ileus (N = 2732; 15.3%) and
digestive system complications (N = 1899; 10.6%), with signif-
icant overlap between the two (N = 1516; 8.5%). A majority of
the patients with POI were male (54.9%), caucasian (70.9%)
and in the 51–64 year age group (51%). The average hospital
LOS was signiﬁcantly higher (p < 0.001) in patients with 
POI (13.6 ± 13.3 days) compared with patients without POI 
(8.6 ± 9.5 days). The average ICU LOS was signiﬁcantly higher
(p < 0.001) in patients with POI (2.4 ± 8.6 days) compared 
with patients without (1.2 ± 9.5 days). Ventilator usage 
was found to be signiﬁcantly higher (p < 0.001) in the POI 
group (17.0%) compared to those without (12.4%). Average
hospitalization costs were signiﬁcantly higher (p < 0.001) in the
patients with POI ($25,089 ± 35,386) than those without POI
($16,907 ± 29,320). CONCLUSION: Post-operative ileus in
colectomy patients is associated with increased hospital resource
utilization. Prevention of POI could reduce hospital length of
stay and costs.
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HEALTH CARE UTILIZATION AND COSTS ASSOCIATED WITH
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COMPARED TO MIGRAINE IN A LARGE MANAGED 
CARE POPULATION
Mitra D1, Davis KL1, Baran RW2
1RTI Health Solutions, Research Triangle Park, NC, USA, 2Takeda
Pharmaceuticals North America, Deerﬁeld, IL, USA
